Li Weizhao, Zhang Chi, Gao Tianshun, Sun Yazhou, Yang Huan, Liu Lixiang, Shi Ming, Ding Lu, Zhang Changlin, Deng David Y B, Li Tian
Department of Gynecology, Pelvic Floor disorders Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen 518107, People's Republic of China.
Shenzhen Key Laboratory of Chinese Medicine Active substance screening and Translational Research, Shenzhen 518107, People's Republic of China.
Stem Cells Transl Med. 2025 Jan 17;14(1). doi: 10.1093/stcltm/szae087.
Cervical cancer is often caused by persistent high-risk human papillomavirus (HPV) infection, causing precancerous lesions. Human umbilical cord mesenchymal stem cells-derived small extracellular vesicles (hucMSC-sEV) exhibit diverse effects on tumors. This study investigates hucMSC-sEV, the impact and mechanisms on HPV-positive cervical precancerous lesion cells to provide new treatment insights.
We previously obtained hucMSC and hucMSC-sEV. In vitro experiments evaluated hucMSC-sEV effects on the proliferation and migration of S12 cells (derived from cervical precancerous lesions). Bioinformatics identified key microRNA components, and their impact on S12 cell proliferation and migration was investigated. The target gene of the microRNA component was predicted and confirmed via bioinformatics and dual-luciferase reporter assays. Lentiviral systems overexpressed target gene in S12 cells to examine the effects on microRNA impacts. SH-42 inhibitor was used to investigate target gene treatment potential. Immunohistochemistry assessed target gene expression in cervical precancerous lesions tissue.
hucMSC-sEV significantly inhibited S12 cell proliferation and migration. Bioinformatics identified miR-370-3p as an effective cargo, which also suppressed S12 cell proliferation and migration. miR-370-3p was confirmed targeting DHCR24 (24-Dehydrocholesterol Reductase). DHCR24 overexpression reversed miR-370-3p's inhibitory effects, while SH-42 counteracted DHCR24 overexpression's promoting effects. Clinical specimen analysis supported these findings, demonstrating a positive correlation between DHCR24 protein expression and cervical precancerous lesions' progression.
hucMSC-sEV inhibits S12 cell proliferation and migration, mediated by miR-370-3p targeting DHCR24 to regulate cellular cholesterol content. DHCR24 inhibition reduces the cholesterol level and cell functions, suggesting its potential as a therapeutic target in cervical precancerous lesions.
宫颈癌常由持续性高危型人乳头瘤病毒(HPV)感染引起,导致癌前病变。人脐带间充质干细胞衍生的小细胞外囊泡(hucMSC-sEV)对肿瘤具有多种作用。本研究旨在探讨hucMSC-sEV对HPV阳性宫颈上皮内瘤变细胞的影响及其机制,为治疗提供新的思路。
我们之前已获取hucMSC和hucMSC-sEV。体外实验评估了hucMSC-sEV对S12细胞(源自宫颈上皮内瘤变)增殖和迁移的影响。通过生物信息学鉴定关键的微小RNA成分,并研究其对S12细胞增殖和迁移的影响。通过生物信息学和双荧光素酶报告基因检测预测并验证微小RNA成分的靶基因。使用慢病毒系统在S12细胞中过表达靶基因,以研究其对微小RNA影响的作用。使用SH-42抑制剂研究靶基因的治疗潜力。免疫组织化学评估靶基因在宫颈上皮内瘤变组织中的表达。
hucMSC-sEV显著抑制S12细胞的增殖和迁移。生物信息学鉴定出miR-370-3p为有效成分,其也抑制S12细胞的增殖和迁移。证实miR-370-3p靶向DHCR24(24-脱氢胆固醇还原酶)。DHCR24过表达逆转了miR-370-3p的抑制作用,而SH-42抵消了DHCR24过表达的促进作用。临床标本分析支持了这些发现,表明DHCR24蛋白表达与宫颈上皮内瘤变的进展呈正相关。
hucMSC-sEV通过miR-370-3p靶向DHCR24调节细胞胆固醇含量,从而抑制S12细胞的增殖和迁移。抑制DHCR24可降低胆固醇水平和细胞功能,提示其在宫颈上皮内瘤变中作为治疗靶点的潜力。